Form 4: CareDx Director George Bickerstaff Receives Significant Restricted Stock Unit Grant

CareDx, Inc. Director George Bickerstaff was granted 12,103 restricted stock units, increasing his beneficial ownership to 115,130 shares.

Summary

• George Bickerstaff, a Director of CareDx, Inc. (CDNA), acquired 12,103 shares of common stock on June 13, 2025.
• The acquisition was a grant of restricted stock units (RSUs) at a price of $0 per share.
• Following this transaction, Mr. Bickerstaff's total beneficial ownership in CareDx, Inc. increased to 115,130 shares.
• The restricted stock units are scheduled to vest in one installment on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally viewed positively as it aligns the director's long-term interests with those of the shareholders and is a standard form of compensation.

Positives

• The grant of restricted stock units to a director aligns the director's long-term interests with those of the shareholders.
• An increase in beneficial ownership by a director, even through a grant, can signal continued commitment and confidence in the company's future prospects.

Risks

• The ultimate value of the restricted stock units is contingent on the future performance of CareDx, Inc.'s stock price.
• The vesting schedule means the director does not immediately have full ownership, and the value could fluctuate significantly before the vesting date.

Future Outlook

The restricted stock units granted to Director George Bickerstaff are scheduled to vest on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Industry Context

The grant of restricted stock units to a director is a common practice in the biotechnology and healthcare diagnostics industry, aligning executive and board member incentives with long-term shareholder value. This type of compensation is standard across many publicly traded sectors.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation practice across publicly traded companies, including those in the biotechnology and healthcare diagnostics sectors.
• While specific grant sizes vary by company size, performance, and individual role, the mechanism of equity-based compensation like RSUs is a widely accepted method to align director interests with shareholder returns.
• No specific comparable companies or projects are detailed in this filing to allow for a direct quantitative comparison of the grant size.

Related Party Transactions

• The grant of restricted stock units to Director George Bickerstaff constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to more focused long-term decision-making and value creation.

Next Steps

• Vesting of the 12,103 restricted stock units on the earlier of June 13, 2026, or the day immediately prior to the first annual meeting of stockholders held by CareDx, Inc. after June 13, 2025.

Key Dates

Keywords

CareDx, CDNA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Stock Grant, Beneficial Ownership